Published in J Lab Clin Med on April 01, 1980
The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci U S A (1985) 2.64
Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. J Clin Invest (1985) 1.79
Substructure of human von Willebrand factor. J Clin Invest (1985) 1.55
Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent. J Clin Invest (1981) 1.44
Analysis of the complexity of the multimeric structure of factor VIII related antigen/von Willebrand protein using a modified electrophoretic technique. J Clin Pathol (1983) 1.03
Structural analysis of factor VIII antigen in von Willebrand disease. Proc Natl Acad Sci U S A (1980) 0.98
Functional domains on von Willebrand factor. Recognition of discrete tryptic fragments by monoclonal antibodies that inhibit interaction of von Willebrand factor with platelets and with collagen. J Clin Invest (1984) 0.94
Electron microscopy of human factor VIII/Von Willebrand glycoprotein: effect of reducing reagents on structure and function. J Cell Biol (1982) 0.88
Botrocetin (venom coagglutinin): reaction with a broad spectrum of multimeric forms of factor VIII macromolecular complex. Proc Natl Acad Sci U S A (1983) 0.87
Collagen binding provides a sensitive screen for variant von Willebrand disease. Clin Chem (2013) 0.84
Heterogeneous distribution of Weibel-Palade bodies and von Willebrand factor along the porcine vascular tree. Am J Pathol (1991) 0.83
Von Willebrand's disease: a clinical and molecular enigma. Twelfth Annual Paul M. Aggeler Memorial Lecture. West J Med (1982) 0.80
Epitope mapping by cDNA expression of a monoclonal antibody which inhibits the binding of von Willebrand factor to platelet glycoprotein IIb/IIIa. Biochem J (1992) 0.77
Simultaneous inheritance and expression of classical haemophilia A and type IIA von Willebrand's disease. J Clin Pathol (1984) 0.75
Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction. N Engl J Med (1994) 7.17
Multiple essential functions of neuregulin in development. Nature (1995) 5.66
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J Cell Biol (2001) 3.84
Deficiency of protein C in congenital thrombotic disease. J Clin Invest (1981) 3.56
Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation (2001) 3.33
Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol (1993) 3.32
Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr (1997) 3.14
Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity (1996) 2.96
Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest (1980) 2.88
Ultrafast bond softening in bismuth: mapping a solid's interatomic potential with X-rays. Science (2007) 2.84
The complex multimeric composition of factor VIII/von Willebrand factor. Blood (1981) 2.76
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost (2006) 2.56
Susceptibility locus for Alzheimer's disease on chromosome 10. Science (2000) 2.49
CYP98A3 from Arabidopsis thaliana is a 3'-hydroxylase of phenolic esters, a missing link in the phenylpropanoid pathway. J Biol Chem (2001) 2.32
Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost (1992) 2.31
Common-sense models of illness: the example of hypertension. Health Psychol (1985) 2.26
Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation (1999) 2.09
Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen-antibody complexes. J Clin Invest (1977) 2.07
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med (1980) 2.07
Blood coagulation initiation by a complement-mediated pathway. J Exp Med (1971) 2.04
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer (1999) 1.99
A blood coagulation abnormality in rabbits deficient in the sixth component of complement (C6) and its correction by purified C6. J Exp Med (1971) 1.97
Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J Cell Biol (1995) 1.91
Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood (1996) 1.89
Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost (2005) 1.88
Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens (2004) 1.86
Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J Biol Chem (1984) 1.83
von Willebrand factor and von Willebrand disease. Blood (1987) 1.83
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost (2008) 1.81
Congenital upper eyelid eversion complicated by corneal perforation. Br J Ophthalmol (2005) 1.73
von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem (1986) 1.71
Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood (2001) 1.69
Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease. J Clin Invest (1976) 1.67
Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest (1978) 1.66
Evidence that the Ya and Yc subunits of glutathione transferase B (ligandin) are the products of separate genes. Eur J Biochem (1982) 1.65
Cost-effectiveness of strategies to enhance mammography use. Eff Clin Pract (2001) 1.65
A novel class C beta-lactamase (FOX-2) in Escherichia coli conferring resistance to cephamycins. Antimicrob Agents Chemother (1997) 1.64
Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblastlike cells. A potential mechanism of self perpetuation in liver fibrogenesis. J Clin Invest (1992) 1.62
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Detection of carriers of classic hemophilia using an immunologic assay for antihemophilic factor (factor 8(). J Clin Invest (1971) 1.61
Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost (2001) 1.60
Structure-function relationship of human von Willebrand factor. Blood (1987) 1.60
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost (1995) 1.58
Determination of the von Willebrand's disease antigen (factor VIII-related antigen) in plasma by quantitative immunoelectrophoresis. J Lab Clin Med (1975) 1.54
Thrombotic risk factors in pulmonary hypertension. Eur Respir J (2000) 1.54
Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood (1984) 1.52
Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell (1985) 1.51
Agriculture. Transforming U.S. agriculture. Science (2011) 1.51
International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost (1993) 1.51
Academic stress, power motivation, and decrease in secretion rate of salivary secretory immunoglobulin A. Lancet (1983) 1.49
Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol (1998) 1.49
Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost (2000) 1.48
Enhanced botrocetin-induced type IIB von Willebrand factor binding to platelet glycoprotein Ib initiates hyperagglutination of normal platelets. Am J Hematol (1990) 1.46
von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease. J Clin Invest (1978) 1.45
Onset of manifestations of hepatic porphyria in relation to the influence of female sex hormones. Arch Intern Med (1966) 1.43
Molecular procedure for rapid detection of Burkholderia mallei and Burkholderia pseudomallei. J Clin Microbiol (1998) 1.42
Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Natl Acad Sci U S A (1982) 1.41
A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem (1987) 1.39
A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans. Eur J Clin Nutr (2007) 1.38
[Nononcologic abdominal surgery in the elderly]. Chirurg (2005) 1.38
Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med (1983) 1.38
Long-term follow-up of Stargardt's disease and fundus flavimaculatus. Ophthalmology (1998) 1.37
Structure of the von Willebrand factor domain interacting with glycoprotein Ib. J Biol Chem (1988) 1.35
Biosynthesis of the subunits of factor VIIIR by bovine aortic endothelial cells. Proc Natl Acad Sci U S A (1983) 1.32
Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood (1990) 1.31
Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood (1982) 1.30
Willebrand factor and ristocetin. I. Mechanism of rustocetin-induced platelet aggregation. Br J Haematol (1974) 1.29
Increased production and expression of tissue thromboplastin-like procoagulant activity in vitro by allogeneically stimulated human leukocytes. J Clin Invest (1978) 1.28
von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest (1986) 1.28
Cloning and developmental expression of the murine neurofilament gene family. Brain Res (1986) 1.28
The zebrafish forkhead transcription factor FoxH1/Fast1 is a modulator of nodal signaling required for organizer formation. Curr Biol (2000) 1.27
Mutations in the catalytic domain of human coagulation factor IX: rapid characterization by direct genomic sequencing of DNA fragments displaying an altered melting behavior. Genomics (1989) 1.26
Factor VIII coagulant activity and factor VIII-like antigen: independent molecular entities. J Exp Med (1973) 1.26
Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med (1982) 1.26
Hereditary deficiency of the seventh component of complement. J Clin Invest (1975) 1.26
Increased von Willebrand factor antigen in the plasma of patients with vasculitis. Arthritis Rheum (1984) 1.25
Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost (2001) 1.25
Factor-VIII-related antigen: multiple molecular forms in human plasma. Proc Natl Acad Sci U S A (1975) 1.24
Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother Rep (1975) 1.24
Haemophilia B due to a de novo insertion of a human-specific Alu subfamily member within the coding region of the factor IX gene. Eur J Hum Genet (1993) 1.24
Independent modulation of von Willebrand factor and fibrinogen binding to the platelet membrane glycoprotein IIb/IIIa complex as demonstrated by monoclonal antibody. J Clin Invest (1985) 1.23
Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC). J Clin Invest (1982) 1.23
Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation. Proc Natl Acad Sci U S A (1985) 1.23
Thrombin proteolysis of purified factor viii procoagulant protein: correlation of activation with generation of a specific polypeptide. Blood (1983) 1.20
Human platelet-initiated formation and uptake of the C5-9 complex of human complement. J Clin Invest (1976) 1.19
Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that of Weibel-Palade bodies. Blood (1985) 1.18
Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Pathol (2005) 1.17
Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites. J Biol Chem (1989) 1.17
Report from a forum on US heart allocation policy. Am J Transplant (2015) 1.17
Elevation of von Willebrand factor is independent of erythrocyte sedimentation rate and persists after glucocorticoid treatment in giant cell arteritis. Arthritis Rheum (1984) 1.16